Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0786)
Drug Name
BRN-0077922
Synonyms
Glycyron; Glycyrrhetinic acid glycoside; Glycyrrhizic acid; Glycyrrhizin [JAN]; Glycyrrhizinic acid; Glycyrrizin; Liquorice; Rizinsan K2 A2 (free acid); beta-Glycyrrhizin; glycyrrhizin; glyzyrrhizin; 1405-86-3; 18-beta-Glycyrrhizic acid; 6FO62043WK; BRN 0077922; C42H62O16; CHEBI:15939; CHEMBL441687; DSSTox_CID_27006; DSSTox_GSID_47006; DSSTox_RID_82047; EINECS 215-785-7; HSDB 496; NSC 167409; NSC 234419; NSC 2800; UNII-6FO62043WK
Indication Influenza virus infection [ICD11: 1E30] Phase 3 [1]
Structure
3D MOL is unavailable 2D MOL
Pharmaceutical Properties Molecular Weight 822.9 Topological Polar Surface Area 267
Heavy Atom Count 58 Rotatable Bond Count 7
Hydrogen Bond Donor Count 8 Hydrogen Bond Acceptor Count 16
Cross-matching ID
PubChem CID
14982
PubChem SID
595979 ; 8145710 ; 8161234 ; 12014953 ; 14767124 ; 14889369 ; 29282971 ; 49974013 ; 53789412 ; 57328816 ; 80458755 ; 87570348 ; 93165815 ; 104069368 ; 104225159 ; 104253562 ; 104335876 ; 117542241 ; 118046163 ; 119525684 ; 124360077 ; 124757704 ; 125164508 ; 126592383 ; 134981322 ; 135985736 ; 137005264 ; 137174069 ; 144205073 ; 144206976 ; 144213802 ; 152032505 ; 152108764 ; 160703999 ; 162037865 ; 162176852 ; 163614442 ; 163883554 ; 175265976 ; 178101402 ; 179316054 ; 184545284 ; 196378207 ; 223673136 ; 223721543 ; 223800488 ; 226407764 ; 249839445 ; 252216692 ; 252391202
ChEBI ID
CHEBI:15939
CAS Number
1405-86-3
TTD Drug ID
D0T8QB
Formula
C42H62O16
Canonical SMILES
CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C
InChI
1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1
InChIKey
LPLVUJXQOOQHMX-QWBHMCJMSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Glucuronic acid DM002511 N. A. Hydrolysis - Hydrolysis 1 [5]
Glycyrrhetinic acid DM002510
10114
Hydrolysis - Hydrolysis 1 [5]
Unclear DM009999 N. A. Conjugation - Sulfation 2 [5]
Unclear DM009999 N. A. Conjugation - Glucuronidation 2 [5]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR000448 BRN-0077922 Glycyrrhetinic acid Hydrolysis - Hydrolysis Unclear [5]
MR000449 BRN-0077922 Glucuronic acid Hydrolysis - Hydrolysis Unclear [5]
MR000447 Glycyrrhetinic acid . Conjugation - Glucuronidation Unclear [5]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A7 (CYP3A7) DME0015 Homo sapiens
CP3A7_HUMAN
1.14.14.1
[2]
Unclear metabolic mechanism (DME-unclear) DME1426 Eubacterium cellulosolvens Not Available Not Available [3]
Unclear metabolic mechanism (DME-unclear) DME1440 Mediterraneibacter glycyrrhizinilyticus Not Available Not Available [4]
References
1 ClinicalTrials.gov (NCT01342185) Efficacy of Medical Ozone Therapy in Patients With Chronic Hepatitis B.
2 Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010 Aug;66(8):805-810.
3 Intestinal bacterial hydrolysis is indispensable to absorption of 18 beta-glycyrrhetic acid after oral administration of glycyrrhizin in rats. J Pharm Pharmacol. 1994 Feb;46(2):135-7.
4 Clostridium glycyrrhizinilyticum sp. nov., a glycyrrhizin-hydrolysing bacterium isolated from human faeces. Microbiol Immunol. 2006;50(7):481-5.
5 DrugBank(Pharmacology-Metabolism)BRN-0077922

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.